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Abstract
Background and Aim: To evaluate if the presence of carotid atherosclerosis in patients with NAFLD, could be related to
gene variants influencing hepatic fat accumulation and the severity of liver damage.
Methods: We recorded anthropometric, metabolic and histological data(Kleiner score) of 162 consecutive, biopsy-proven
Sicilian NAFLD patients. Intima-media thickness(IMT), IMT thickening(IMT$1 mm) and carotid plaques(focal thickening of
.1.3 mm at the level of common carotid artery) were evaluated using ultrasonography. IL28B rs12979860 C.T, PNPLA3
rs738409 C.G, GCKR rs780094 C.T, LYPLAL1 rs12137855 C.T, and NCAN rs2228603 C.T single nucleotide polymorphisms
were also assessed. The results were validated in a cohort of 267 subjects with clinical or histological diagnosis of NAFLD
from Northern Italy, 63 of whom had follow-up examinations.
Results: Carotid plaques, IMT thickening and mean maximum IMT were similar in the two cohorts, whereas the prevalence
of diabetes, obesity, NASH, and PNPLA3 GG polymorphism(21%vs.13%, p = 0.02) were significantly higher in the Sicilian
cohort. In this cohort, the prevalence of carotid plaques and IMT thickening was higher in PNPLA3 GG compared to CC/CG
genotype(53%vs.32%, p = 0.02; 62%vs.28%, p,0.001, respectively). These associations were confirmed at multivariate
analyses (OR2.94;95%C.I. 1.12–7.71, p = 0.02, and OR4.11;95%C.I. 1.69–9.96, p = 0.002, respectively), although have been
observed only in patients ,50years. Also in the validation cohort, PNPLA3 GG genotype was independently associated with
IMT thickening in younger patients only (OR: 6.00,95%C.I. 1.36–29, p = 0.01), and to IMT progression (p = 0.05) in patients
with follow-up examinations.
Conclusion: PNPLA3 GG genotype is associated with higher severity of carotid atherosclerosis in younger patients with
NAFLD. Mechanisms underlying this association, and its clinical relevance need further investigations.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) affects about 20%–
30% of the general population. [1] In addition to being at risk for
non-alcoholic steatohepatitis (NASH), leading to cirrhosis and its
complications, [1] NAFLD patients are also at higher risk of
systemic and cardiovascular diseases. [2] Specifically, surrogate
markers of NAFLD, namely fatty liver index, [3] and elevated
ALT [4] and GGT [5] have been associated with carotid
atherosclerosis and incident cardiovascular disease, respectively.
Similarly, NAFLD, diagnosed either by ultrasonography or by
liver biopsy, has been associated with a higher prevalence of early
asymptomatic cardiovascular alterations such as altered left
ventricular geometry and early features of left ventricular diastolic
dysfunction, [6,7] low coronary flow reserve [8] and coronary
calcification, [9] and carotid atherosclerosis.[10–12] These alter-
ations have been partly associated with the severity of liver
damage, measured by both lobular inflammation and fibrosis.
Cross sectional studies demonstrated a link between NAFLD and
the presence/extent of coronary, cerebral and peripheral cardio-
vascular involvement, [13] whereas prospective studies identified
NAFLD as risk factor for cardiovascular events after correction for
conventional confounders. [14].
In the last few years, data arising from genome-wide (GWAS) or
candidate association studies identified single nucleotide polymor-
phisms (SNPs) in genes involved in metabolic homeostasis,
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inflammation, oxidative stress and fibrogenesis, as associated with
NAFLD and its severity. Patatin-like phospholipase-3 (PNPLA3)/
adiponutrin, rs738409 C.G SNP, remains the most validated risk
gene in this setting. [15,16] Because NAFLD is the liver expression
of a systemic metabolic dysregulation, we hypothesized that SNPs
of genes associated with NAFLD and its severity -PNPLA3,
GWAS-derived genes like neurocan (NCAN), glucokinase regula-
tory protein (GCKR), lysophospholipase-like 1 (LYPLAL1) [17],
and IL28B which have been recently associated with hepatic
lobular inflammation and fibrosis [18] - could also be linked to the
severity of systemic, and in particular cardiovascular alterations in
this setting of patients.
We evaluated carotid atherosclerosis in an homogeneous cohort
of biopsy-proven NAFLD patients, in order to assess its correlation
with gene variants influencing hepatic fat accumulation and the
severity of liver damage in NAFLD. The results were raised and
validated in two totally independent cohorts.
Materials and Methods
The study was performed in accordance with the principles of
the Declaration of Helsinki and its appendices, and with local and
national laws. Approval was obtained from the AOUP Policlinico
Paolo Giaccone of Palermo and from the Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico Milan, Institutional
Review Boards and Ethics Committees, and written informed
consent was obtained from all patients.
Patients
We analyzed data from 429 Italian consecutive patients with
NAFLD and with available DNA and ultrasonographic carotid
arteries assessment. Among them, 162 patients with clinical and
histological diagnosis of NAFLD were prospectively recruited at
the Gastrointestinal & Liver Unit of the Palermo University
Hospital (training set)., and 267 patients were recruited at the
Metabolic Liver Diseases outpatient service, Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, Milan (validation
set),. The latter has already been included in a previous study on
cardiovascular risk factors for NAFLD. [19] Other causes of liver
disease were excluded, including alcohol intake (.20 g/day)
evaluated by a questionnaire, viral and autoimmune hepatitis,
hereditary hemochromatosis, and alpha1-antitrypsin deficiency.
Patients with advanced cirrhosis, hepatocellular carcinoma,
current use of drugs interfering with lipid metabolism (i.e., statins,
fibrates) (only for Sicilian patients), and previous diagnosis of
carotid atherosclerosis, were excluded.
Clinical, Laboratory and Histological Assessment
Clinical and anthropometric data, including BMI, the presence
of arterial hypertension and type 2 diabetes, were collected at the
time of enrollment. [20] A 12-hour overnight fasting blood sample
was drawn to determine serum levels of ALT, total, HDL and
LDL-cholesterol, triglycerides, ferritin, GGT, plasma glucose
concentration, and insulin. Insulin resistance was determined by
the homeostasis model assessment (HOMA). [21] Serum adipo-
nectin (SPIbio – Bertin Pharma Human Adiponectin EIA Kit)
levels were measured in duplicate in the Sicilian patients.
Slides were coded and read at each clinical center by one expert
pathologist, who was unaware of patients identity and history. A
minimum 15 mm-length of the biopsy specimen or the presence of
at least 10 complete portal tracts was required. [22] Steatosis was
assessed as the percentage of hepatocytes containing fat droplets
(minimum 5%), and evaluated as a continuous variable. Kleiner
classification [23] was used to compute the NAFLD activity score
(NAS) (from 0 to 8, on a scale including separate scores for
steatosis, lobular inflammation, and hepatocellular ballooning) and
to stage fibrosis from 0 to 4. NASH was considered to be present
when steatosis, ballooning, and lobular inflammation were present.
Genetic Analyses
DNA was extracted from peripheral blood collected at the time
of enrollment in both Sicilian and Northern Italy cohorts.
Genotyping for IL28B (rs12979860), PNPLA3 (rs738409),
GCKR (rs780094), LYPLAL1 (rs12137855), and NCAN
(rs2228603) was carried out using the TaqMan SNP genotyping
allelic discrimination method (Applied Biosystems, Foster City,
CA, USA). Commercial genotyping assays were available for the
following SNPs: rs738409 (cat. C_7241_10), rs780094 (cat.
C_2862873_10), rs12137855 (cat. C_31403184_10), rs2228603
(cat. C_16171492_10). A custom assay was created by Applied
Biosystem for rs12979860. The genotyping call was done with
SDS software v.1.3.0 (ABI Prism 7500, Foster City, CA, USA).
Genotyping was conducted in a blinded fashion relative to
patient characteristics.
Carotid Artery Evaluation
Carotid atherosclerosis was evaluated by an expert physician in
each clinical centre, in a blinded fashion as to characteristic of
patients, using a high-resolution B-mode ultrasonography
equipped with a multifrequency linear probe.
Carotid arteries were investigated in longitudinal projections of
both the left and right side at the level of the common carotid
artery, of the bulb and of the internal carotid. The carotid intima-
media thickness (IMT) was measured as the difference between the
first (intima-lumen) and the second (media-adventitia) interface on
the far wall of the common carotid artery in a section free of
plaques beginning 10 mm below their bifurcations and including
the bifurcations for 10 mm. For each subject, three measurements
on both sides were performed, i.e., the anterior, lateral, and
posterior projection of the near and far wall. Maximum (outside
the plaque) rather than mean values of IMT were considered, and
edge detection was performed manually. IMT measurements from
the left and right side were averaged. Carotid thickening was
defined as an IMT$1 mm; this value has been previously
associated with a higher cardiovascular risk. [24,25] A carotid
plaque was defined as a focal thickening .1.3 mm at the level of
either common and internal carotid arteries or bifurcations. [12].
Statistics
Continuous variables were summarized as mean 6 SD, and
categorical variables as frequency and percentage. The ANOVA
test, student’s t-test and chi-square test were used when
appropriate.
Multiple logistic regression models were used to assess the
relationship of IMT thickening ($1 mm), and carotid plaques with
clinical, biochemical, genetic (PNPLA3 only in Milan patients) and
histological parameters in both NAFLD cohorts. In the first model,
the dependent variable was the presence of an IMT thickening
coded as 0 = IMT,1 mm vs 1 = IMT$1. In the second model,
the dependent variable was the presence of one or more carotid
plaque, coded as 1 = present vs. 0 = absent. As candidate risk
factors, we selected age, gender, BMI, baseline ALT, triglycerides,
total, HDL and LDL cholesterol, GGT, ferritin, blood glucose,
diabetes, arterial hypertension, smoking, insulin, HOMA, adipo-
nectin (only in Palermo patients), IL28B rs12979860 (only in
Sicilian patients), PNPLA3 rs738409, GCKR rs780094 (only in
Sicilian patients), LYPLAL1 rs12137855 (only in Sicilian patients),
NCAN rs2228603 (only in Sicilian patients), and histological
Atherosclerosis, PNPLA3 and NAFLD
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Table 1. Baseline Demographic, Laboratory, Metabolic, Genetic and Histological Features of 429 Italian Patients with Non-alcoholic
Fatty Liver Disease.
Variable
Non-alcoholic Fatty Liver
Disease (Sicily n=162)
Non-alcoholic Fatty Liver
Disease (Northern Italy n =267) P value
Mean Age – years 47.2612.8 52.9612.4 ,0.001
Age$50 years 74 (45.7) 154 (57.6) 0.02
Male Gender 102 (63) 217 (81) ,0.001
Mean Body Mass Index – Kg/m2 30.064.9 27.567.9 ,0.001
Body Mass Index – Kg/m2
,25 20 (12.3) 81 (30.3)
25–29.9 70 (43.2) 137 (51.3)
$30 72 (44.5) 49 (18.4) ,0.001
Arterial Hypertension 46 (28.4) 93 (34.8) 0.20
Type 2 Diabetes 29 (17.9) 21 (8.0) 0.002
Smoking 27 (16.7) 72 (27.0) 0.01
Statin use 0 (0) 22 (8) ,0.001
Carotid Intima-Media Thickness – mm 0.8560.24 0.8660.23 0.66
Carotid thickening 57 (35.2) 90 (33.7) 0.83
Carotid Plaques 59 (36.4) 84 (31) 0.29
Alanine Aminotransferase – IU/mL 77648 39625 ,0.001
Cholesterol – mg/Dl 205.6647.0 202.6633.7 0.44
HDL Cholesterol – mg/Dl 51619 43614 ,0.001
LDL Cholesterol – mg/Dl 126639 126633 0.99
Triglycerides – mg/Dl 145677 139674 0.37
Blood Glucose – mg/Dl 99.0628.2 95.2616.3 0.07
Insulin – mU/Ml 16.569.7 16.9610.3 0.69
HOMA Score 4.1463.14 4.263.7 0.86
Hyperferritinemia 52 (32.1) 121 (45.3) 0.009
IL28B rs12979860 polymorphism
C/C 74 (45.7) –
T/C 74 (45.7) –
T/T 14 (8.6) – –
PNPLA3 rs738409 polymorphism
C/C 53 (32.7) 113 (42)
C/G 75 (46.3) 121 (45)
G/G 34 (21.0) 33 (13) 0.02
GCKR rs780094 polymorphism
C/C 24 (14.8) –
C/T 84 (51.9) –
T/T 54 (33.3) – –
LYPLAL1 rs12137855 polymorphism
C/C 95 (58.6) –
C/T 64 (39.5) –
T/T 3 (1.9) – –
NCAN rs2228603 polymorphism
C/C 145 (89.5) –
C/T 17 (10.5) –
T/T 0 (0.0) – –
Histology*
NAFLD activity score (NAS)
1–2 17 (10.5) 97 (76.0)
3–4 44 (27.2) 23 (18.3)
Atherosclerosis, PNPLA3 and NAFLD
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variables like steatosis, lobular inflammation, hepatocellular
ballooning, NAS score, NASH, and fibrosis (for all Sicilian
patients, and for the Northern Italian patients who underwent liver
biopsy).
Multiple linear regression analysis was done to identify
independent predictors of IMT (continuous dependent variable)
in both cohorts of NAFLD patients. As candidate risk factors, we
selected the same independent variables included in the logistic
model.
In all models, we compared patients homozygous for at-risk
alleles to all other variants. [15].
Regression analyses were done using Proc Logistic, Proc Reg,
and subroutine in SAS (SAS Institute, Inc., Cary, North Carolina,
U.S.A.). [26].
Results
Patient Features and Histology
The baseline features of the 162 Sicilian (training set) and the
267 Northern Italian (validation set) patients are shown in Table 1.
Sicilian patients were younger, comprised a larger prevalence of
females and of subjects with metabolic alterations (obesity and
diabetes), and had higher ALT serum levels compared to Northern
Italian patients.
Comparing Sicilian patients with the Northern Italian cases
with liver biopsy, we have found a more severe spectrum of liver
disease, i.e. more severe steatosis, lobular inflammation, fibrosis
and obviously a higher prevalence of NASH, but a lower
prevalence of hyperferritinemia.
The genetic frequency of the polymorphisms tested in Sicilian
and Northern Italian cohorts are reported in Table 1. Specifically,
PNPLA3 rs738409 GG genotype was present in 34 (21%) of
Sicilian, compared to 33 (13%) of Northern Italy patients
(p = 0.02). Genetic frequencies of the five polymorphisms tested
in the Sicilian cohort fit with the Hardy–Weinberg equilibrium
(x2 = 1.08 for IL28B rs12979860, x2 = 0.10 for PNPLA3 rs738409;
x2 = 0.35 for GCKR rs780094; x2 = 0.71 for LYPLAL1
rs12137855; x2 = 0.22 for NCAN rs2228603; p.0.05 for all), as
well as genetic frequency of PNPLA3 SNP tested in the Northern
Italy cohort (x2 = 0, p.0.05).
Factors Associated with Carotid Atherosclerosis
The prevalence of carotid plaques was similar in Sicilian and
Northern Italian patients (36% vs. 31%; p = 0.29), as well as that of
Table 1. Cont.
Variable
Non-alcoholic Fatty Liver
Disease (Sicily n=162)
Non-alcoholic Fatty Liver
Disease (Northern Italy n =267) P value
5–8 101 (62.3) 7 (5.6) ,0.001
Lobular inflammation
0 12 (7.4) 50 (39.7)
1 77 (47.5) 70 (55.6)
2 66 (40.7) 6 (2.7)
3 7 (4.3) 0 ,0.001
Steatosis grade
1 (5%–33%) 57 (35.2) 74 (58.7)
2 (.33%–66%) 49 (30.2) 40 (31.7)
3 (.66%) 56 (34.6) 12 (9.6) ,0.001
Hepatocellular ballooning
0 13 (8.0) 103 (87.7)
1 75 (46.3) 23 (22.3)
2 74 (45.7) 0 ,0.001
NASH
present 160 (98.8) 58 (46)
absent 2 (1.2) 68 (54) ,0.001
Stage of Fibrosis
0 45 (27.8) 58 (46.0)
1 39 (24.1) 43 (34.2)
2 38 (23.5) 18 (14.2)
3 27 (16.7) 3 (2.3)
4 13 (8.0) 4 (3.2) ,0.001
Abbreviation: IU, international units; HOMA, homeostasis model assessment; LDL, low density lipoprotein; HDL, high density lipoprotein; IL28B: interleukin 28B; PNPLA3:
patatin-like phospholipase-3; GCKR: glucokinase regulatory protein; LYPLAL1: lysophospholipase-like 1; NCAN: neurocan. Data are given as mean 6 standard deviation,
median {interquartile range}, or as number of cases (%).
*Histological data are available for all Sicilian patients, and for 126 Northern Italy patients.
doi:10.1371/journal.pone.0074089.t001
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carotid thickening (35% vs. 34% p = 0.83), and mean maximum
IMT (0.8560.24 mm vs. 0.8660.23 mm; p = 0.66). No study
participants had clinically relevant carotid stenosis (i.e., $60%).
In the Sicilian cohort the prevalence of carotid plaques and
carotid thickening was higher in patients with PNPLA3 GG
compared to those with CC and CG genotype (523% vs. 32%,
p = 0.02; and 62% vs. 28%, p,0.001, respectively) (Figure 1A and
1B). The association was only observed in patients younger than
50 (40% vs. 11%, p = 0.005 for carotid plaques; and 53% vs. 14%,
p = 0.001 for IMT thickening), but not in those older than50 years
(63% vs. 60%, p = 0.75 for carotid plaques; and 68% vs. 47%,
p = 0.11 for IMT thickening) (Figure 1A and 1B). At multivariate
logistic regression analyses, PNPLA3 GG genotype remained
independently associated with the above quoted features (OR
2.94; 95% C.I. 1.12–7.70, p = 0.02 for carotid plaques, and OR
3.86; 95% C.I. 1.62–9.15, p = 0.002 for carotid thickening),
together with age$50 years (OR 5.39; 95%C.I. 2.14–13.5,
p,0.001) and diabetes (OR 5.29; 95% C.I. 1.51–18.5,
p = 0.009) for carotid plaques (Table 2), and with age $50 years
(OR 4.25; 95%C.I. 1.88–9.62, p = 0.001) and LDL (OR 1.01;
95%C.I. 1.00–1.02, p = 0.007) for carotid thickening (Table 3).
After Bonferroni correction, the link between PNPLA3 GG
genotype and carotid alterations, was maintained for carotid
thickening (p = 0.01), but not for carotid plaques (p = 0.10).
Interestingly, no association was found between carotid alterations
and both adiponectin serum levels (6.262.1 vs. 5.962.2, p = 0.41
for absence/presence of carotid plaques; 6.162.0 vs. 6.062.3,
p = 0.78 for absence/presence of carotid thickening), serum
ferritin (2586184 vs. 2986361, p = 0.44 for absence/presence of
carotid plaques; 2456200 vs. 3356364, ng/ml, p = 0.11 for
absence/presence of carotid thickening), and the other studied
SNPs (Table S1).
Among histological features, both moderate-severe lobular
inflammation and severe fibrosis were associated with the presence
of carotid plaques even if this link was not maintained at
multivariate analysis (Table 2). When considering separately
patients ,50 and $50 years, PNPLA3 GG genotype remained
independently linked to both carotid plaques (OR 5.00, 95%C.I.
1.24–20.1; p = 0.02) (Table S2) and carotid thickening (OR 7.46,
95%C.I. 1.96–28.3; p = 0.003) (Table 3) in patients younger 50
years only.
In the validation cohort from Northern Italy, the prevalence of
carotid plaques and carotid thickening was not significantly
different according to the presence/absence of PNPLA3 GG
genotype (24% vs. 33%, p = 0.32; and 30% vs. 34%, p = 0.69,
respectively), but a significant difference was observed for carotid
thickening in patients younger than 50 years (26% vs. 8%,
p = 0.04) (Figure 1A and 1B). When the PNPLA3 GG genotype
was forced into the carotid plaque model, the polymorphism was
not associated with carotid plaques, while an independent
association was observed for age $50 years (OR 7.91, 95%C.I.
3.72–18.3, p,0.001), ferritin (OR 1.96, 95%C.I. 1.41–2.83,
p,0.001), and arterial hypertension (OR 2.08, 95%C.I. 1.11–
3.89, p = 0.02) (Table 2). By contrast, when the PNPLA3 GG
genotype and its term of interaction with age was forced into the
carotid thickening model, the interaction term (p = 0.02) resulted
independently associated with carotid thickening together with
age$50 years (OR 6.43, 95% C.I. 3.23–13.6, p =,0.001) and
LDL (OR 1.01, 95% C.I. 1.00–1.02, p = 0.04) (Table 3).
Accordingly, considering separately patients ,50 and $50 years,
PNPLA3 GG genotype remained independently associated with
carotid thickening in patients younger than 50 years (OR 6.00,
95% C.I. 1.36–29, p = 0.01), but not in their older counterpart
(OR 0.54, 95% C.I. 0.15–1.78, p = 0.35) (Table 3).
In the analysis using IMT as a continuous variable, Sicilian
patients with PNPLA3 CC/CG genotype had a lower mean
maximum IMT than their counterpart with PNPLA3 GG
genotype (0.8260.23 vs. 0.9460.25, p = 0.01). Again, this differ-
ence is significant in patients younger than 50 years (0.7560.17 vs.
0.8560.25, p = 0.05), not in those older (0.9360.25 vs. 1.0060.26,
Figure 1. Carotid atherosclerosis in Sicilian and Northern
Italian NAFLD patients according to age and to PNPLA3
genotype. Prevalence of carotid artery plaques according to age and
to PNPLA3 genotype (A). Prevalence of carotid thickening according to
age and to PNPLA3 genotype (B). Mean maximum intima-media
thickness values according to age and to PNPLA3 genotype (C).
doi:10.1371/journal.pone.0074089.g001
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p = 0.32) (Figure 1C). Older age (p = 0.001), higher LDL
cholesterol (p = 0.04) and PNPLA3 GG genotype (p = 0.03) were
independent factors associated with high IMT at multiple linear
regression analysis. The link between PNPLA3 GG genotype and
higher IMT was not maintained after Bonferroni correction
(p = 0.15). No association was found in this cohort between IMT
and adiponectin, ferritin serum levels, the other studied SNP, and
histological features (p.0.10). In Northern Italian patients mean
maximum IMT values were similar in patients with and without
PNPLA3 GG genotype (0.8560.21 in GG vs. 0.8760.24 in CC/
CG p = 0.87), even if a weak trend was observed in patients ,50
years (0.7960.21 in GG vs. 0.7260.19 in CC/CG, p = 0.19)
(Figure 1C). When PNPLA3 genotype was forced in the model, it
was not significantly associated with higher IMT (p = 0.32), but
IMT was independently linked to older age (p,0.001) and higher
LDL serum levels (p,0.001).
A subgroup of 63 Northern Italy patients underwent ultraso-
nographic follow-up of carotid assessment. At the baseline, they
were characterized by a slightly younger age (age .50, 19/
63 = 46% vs. 125/204 = 61% of the rest of the cohort; p = 0.04),
and by a lower prevalence of altered iron metabolism (hyperferri-
tinemia, 17/63 = 27% vs. 104/204 = 51%; p,0.001), but with
similar sex distribution, BMI, lipid levels, smoking status, liver
enzymes and prevalence of NASH, basal IMT thickness and
prevalence of plaques (p.0.5 for all). In this cohort, PNPLA3 GG
was at risk for IMT progression (Figure 2) compared to CG and
CC genotypes (p = 0.02). In particular PNPLA3 GG genotype
(p = 0.05), together with age.50 years (p = 0.03) was indepen-
dently associated with IMT progression by multivariate linear
regression analysis (Table 4).
Discussion
In a Sicilian cohort of biopsy-proven NAFLD patients, carotid
atherosclerosis was independently associated not only with well-
known risk factors for atherosclerosis, but also with the PNPLA3
GG genotype; this association was only observed in younger
patients. Of note, this feature was validated in an independent
cohort of Northern Italian NAFLD patients, where PNPLA3 GG
genotype was also associated with atherosclerosis progression.
Different lines of evidence, including cross sectional and
prospective studies, showed that NAFLD patients are at high risk
of cardiovascular dysfunction/events, identifying conventional
cardiometabolic alterations and the severity of liver damage as
risk factors.[2–14] To the best of our knowledge this is first study
assessing carotid atherosclerosis as a function of gene variants at
risk for NAFLD. The novel finding, limited to a cohort of biopsy-
proven Sicilian NAFLD patients, is the independent association
between the presence of carotid plaques or larger IMT and
PNPLA3 GG genotype. Of note this link was maintained after
adjustment for well-known cardiovascular risk factors, including
lipid levels and IR - not associated in our cohort to PNPLA3
genotype (data not shown) - and histological features of NAFLD.
In particular we found that only 10% of patients ,50 years
carrying the PNPLA3 CC/CG genotype had carotid plaques,
compared with 40% in the group carrying the PNPLA3 GG
genotype. This figure is close to the value observed in the subgroup
of patients $50 years (again, about 60%), irrespective of the
PNPLA3 genotype. These data were also confirmed when
considering IMT$1 mm, and high maximum IMT instead of
carotid plaques. Interestingly, in the validation cohort of Northern
Italian NAFLD patients, vascular alterations were also not
different according to PNPLA3 genotype in the total population,
but in patients younger than 50 a link between atherosclerosis and
PNPLA3 GG genotype was again observed, and maintained after
correction for well known risk factors. The weaker association
between PNPLA3 genotype and carotid atherosclerosis in
Northern Italian, compared to Sicilian patients, could be
expression of the lower prevalence of PNPLA3 GG genotype,
metabolic dysfunctions and severity of liver disease observed in the
validation cohort. In any case, results from both populations are
finally consonant, and data from the Northern Italy NAFLD also
demonstrated an independent association between PNPLA3 GG
genotype and IMT progression over time in a subgroup of patients
characterized by young age at presentation.
Table 2. Multivariate Analysis of Risk Factors Associated with the Presence of Carotid Plaques in 429 Italian Patients with Non-
alcoholic Fatty Liver Disease.
Sicilian NAFLD Cohort Northern Italian NAFLD Cohort
(n=162) (n =267)
Multivariate Analysis Multivariate Analysis
Variable OR (95% CI) p value Variable OR (95% CI) p value
Age $50 years 5.39 (2.14–13.5) ,0.001 Age .50 years 7.91(3.72–18.3) ,0.001
Femal Gender 2.10 (0.91–4.87) 0.08 BMI Kg/m2 1.00(0.97–1.05) 0.95
Arterial Hypertension 0.86 (0.34–2.13) 0.75 Arterial Hypertension 2.08(1.11–3.89) 0.02
Type 2 Diabetes 5.29 (1.51–18.5) 0.009 ALT– IU/Ml 1.00(0.99–1.01) 0.86
Alanine Aminotransferase – IU/L 0.99 (0.98–1.00) 0.08 LDL mg/dl 0.99(0.99–1.01) 0.88
LDL Cholesterol – mg/dL 1.00 (0.99–1.01) 0.17 Ferritin log ng/ml 1.96(1.41–2.83) ,0.001
Blood Glucose – mg/dL 0.99 (0.97–1.00) 0.39 PNPLA3 GG genotype 1.15(0.42–3.34) 0.49
PNPLA3 GG genotype 2.94 (1.12–7.70) 0.02
Lobular inflammation grade 2–3 1.43 (0.59–3.49) 0.42
Severe Liver Fibrosis 1.09 (0.41–2.91) 0.85
Abbreviation: IU, international units; BMI, body mass index; LDL, low density lipoprotein; ALT, alanine aminotransferase; PNPLA3: patatin-like phospholipase-3.
doi:10.1371/journal.pone.0074089.t002
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Although this study was merely observational and not designed
to explore the reasons for the association of atherosclerosis markers
with PNPLA3 genotype, some hypotheses can be proposed. A
recent study by Valenti and colleagues showed that PNPLA3
variant was directly related to hepatic apoptosis in NAFLD. [15]
According to these data, it is plausible to hypothesize that
PNPLA3 genotype, by regulating apoptotic activity - a finding also
involved in the pathogenesis of atherosclerosis [27] -, might
modulate vascular damage. PNPLA3 gene variants in individual
patients might increase lipid storage in the arterial vessels, similar
to that observed in the liver, and could also induce release of
ICAM-1, an endothelium-derived inflammatory marker that has
been associated with myocardial infarction and stroke. [28]
Finally, considering that the mechanisms linking the severity of
NAFLD to the PNPLA3 genotype are largely unknown, we might
also hypothesize that the same pathway generating liver disease
might also produce vascular damage.
The association of PNPLA3 GG genotype with atherosclerosis
limited to younger patients is intriguing. A possible hypothesis
would be that in younger patients, where the role of aging and
classic atherosclerosis risk factors are weaker, PNPLA3 can fully
exert its atherogenic role; in older patients, as effect of PNPLA3-
induced liver disease progression, the reduction of LDL levels
(115.1638.6 mg/dl in F3–F4 vs. 128.9638.2 mg/dl in F0–F2
Sicilian cohort) [29] and arterial pressure values associated with
advanced liver disease might counterbalance the potential
atherogenic role of the PNPLA3 genotype, vanishing the
differences in IMT of the different polymorphisms.
We confirmed that type 2 diabetes and higher LDL cholesterol
levels in the Sicilian cohort, as well as arterial hypertension, higher
Table 3. Multivariate Analysis of Risk Factors Associated with the Presence of Carotid Thickening in 429 Italian Patients with Non-
alcoholic Fatty Liver Disease, considered overall or according to age.
Sicilian NAFLD Cohort Northern Italian NAFLD Cohort
(n=162) (n=267)
Multivariate Analysis Multivariate Analysis
Variable OR (95% CI) p value Variable OR (95% CI) p value
Age $50 years 4.25 (1.88–9.62) 0.001 Age .50 years 6.43(3.23–13.6) ,0.001
Arterial Hypertension 0.98 (0.41–2.31) 0.96 BMI Kg/m2 0.99(0.94–1.03) 0.58
LDL Cholesterol – mg/dL 1.01 (1.00–1.02) 0.007 Arterial Hypertension 1.39(0.76–2.52) 0.29
PNPLA3 GG genotype 3.86 (1.62–9.15) 0.002 ALT IU/Ml 0.99(0.98–1.02) 0.49
LDL mg/dl 1.01(1.00–1.02) 0.04
Ferritin log ng/ml 1.19(0.90–1.59) 0.18
PNPLA3 GG genotype 1.32(0.52–3.32) 0.49
Interaction Age.50*PNPLA3G/G 0.02
Sicilian NAFLD Cohort ,50 years Northern Italian NAFLD Cohort ,50 years
(n=88) (n=113)
Multivariate Analysis Multivariate Analysis
Variable OR (95% CI) p value Variable OR (95% CI) p value
Blood Glucose – mg/dL 1.00 (0.98–1.03) 0.41 BMI Kg/m2 0.99 (0.93–1.07) 0.94
LDL Cholesterol – mg/dL 1.02 (1.00–1.04) 0.01 Arterial Hypertension 1.18 (0.24–7.74) 0.84
PNPLA3 GG genotype 7.46 (1.96–28.3) 0.003 ALT IU/Ml 0.99 (0.96–1.04) 0.72
LDL mg/dl 1.02 (1.00–1.04) 0.01
Ferritin log ng/ml 1.70 (0.90–2.06) 0.12
PNPLA3 148 M/M 6.00 (1.36–29) 0.01
Sicilian NAFLD Cohort $50 years Northern Italian NAFLD Cohort $50 years
(n=74) (n=154)
HOMA 0.89 (0.76–1.05) 0.18 BMI Kg/m2 0.99 (0.94–1.03) 0.52
PNPLA3 GG genotype 2.13 (0.66–6.83) 0.20 Arterial Hypertension 1.46 (0.75–1.81) 0.26
Grade 2–3 Lobular Inflammation 0.46 (0.16–1.27) 0.15 ALT IU/Ml 0.99 (0.99–1.01) 0.79
LDL mg/dl 1.01 (0.99–1.01) 0.37
Ferritin log ng/ml 1.12 (0.87–1.57) 0.47
PNPLA3 148 M/M 0.54 (0.15–1.78) 0.35
Abbreviation: IU, international units; BMI, body mass index; LDL, low density lipoprotein; ALT, alanine aminotransferase; PNPLA3: patatin-like phospholipase-3.
doi:10.1371/journal.pone.0074089.t003
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LDL cholesterol and ferritin levels in the Northern Italian cohort,
were all independent risk factors for carotid atherosclerosis.
Interestingly, in the Sicilian population, even if not maintained
at multivariate analysis, we also observed an association between
carotid plaques and the severity of both liver lobular inflammation
and fibrosis, as also reported by Targher et al. [11] Due to the
very high prevalence of NASH in the Sicilian cohort, we cannot
evaluate the potential association between atherosclerosis and the
diagnosis of NASH. Finally, in the test cohort, we did not find any
association between carotid atherosclerosis and other SNP
promoting NAFLD and its severity. Accordingly GCKR,
LYPLAL, NCAN and IL28B gene variants might exert their
pathogenic effect mainly in the liver, without (in)directly affecting
vascular endothelium.
From a clinical point of view, our data confirm that NAFLD
patients are at high risk of carotid atherosclerosis, especially in the
presence of classical risk factors, in younger patients with PNPLA3
GG genotype, and in patients aged 50 or more. The lack of
association between PNPLA3 GG genotype and atherosclerosis in
older patients, together with the selection of a population at high
cardiovascular risk (i.e. NAFLD/NASH), could explain why the
I148M PNPLA3 gene variant was not identified as a risk factor for
cardiovascular diseases/events in GWAS studies, [30,31] other
than a recent report observing a link between ICAM-1 serum
levels and PNPLA3 genotype in a large cohort of healthy women.
Accordingly, the clinical significance of our data need to be
assessed with caution. Further prospective large scale studies,
assessing separately younger and older patients are needed to
clarify the effect on cardiovascular outcomes, and the importance
of a more intensive diagnostic workload and follow-up to prevent
cardiovascular complications in selected NAFLD groups according
to PNPLA3 genotype.
The main limitation of this study lies in its cross-sectional
nature, unable to identify pathogenic mechanisms(s) linking
PNPLA3 genotype and carotid atherosclerosis, and in the relative
low number of patients younger 50 years. A further methodolog-
ical question is the potentially limited external validity of the
results caused by the small sample of patients especially when
considering subgroup analyses according to age. Our study
included two cohorts of Italian NAFLD patients, largely
overweight-obese, who may be different, in terms of both
metabolic features and severity of liver disease, from the majority
of prevalent cases of NAFLD in the general population. The lack
of data on a control Sicilian population might further limit the
strength of our results; however considering the data published
from our group, [32] we can observe that our NAFLD population
had similar mean IMT and a higher prevalence of carotid plaques,
compared to an older control population, [32] and a higher
prevalence of PNLA3 GG genotype compared to a cohort of 258
Sicilian CHC patients followed at our center (21%vs 9%)
(unpublished data). Obviously, only a case control study could
assess if the higher prevalence of carotid atherosclerosis observed
in NAFLD [2] compared to individuals without steatosis, is related
to an higher prevalence of PNPLA3 genotype and risk of
cardiovascular disease. Finally, we also need data on serum levels
Figure 2. Effect of PNPLA3 CG polymorphism on carotid intima-media thickness progression in 63 Northern Italy patients with
NAFLD.
doi:10.1371/journal.pone.0074089.g002
Table 4. Independent predictors of CC-IMT progression over
time (mm/year) in 63 patients with NAFLD from Northern
Italy.
Variable Estimate coefficient P value
Age $50 years 20.0860.03 0.030
Arterial Hypertension +0.0560.03 0.13
Smoking 0.0660.03 0.14
PNPLA3 GG genotype +0.0960.04 0.050
Abbreviation: PNPLA3: patatin-like phospholipase-3.
doi:10.1371/journal.pone.0074089.t004
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and liver expression of markers of dysmetabolic function and
proinflammatory cytokines potentially involved in the cardiovas-
cular alterations of NAFLD patients.
In conclusion, in two cohorts of Sicilian and Northern Italian
NAFLD patients, we showed that PNPLA3 GG genotype is
associated with a high risk of carotid atherosclerosis in patients
younger than 50. Mechanisms underlying this association, and
whether PNPLA3 genotype also influences cardiovascular events
need to be further investigated.
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